Acurx Pharma Delivers Compelling Ibezapolstat Data

Weak broader markets are creating opportunities. One is in Acurx Pharma. On Monday, the company posted Phase 2a data demonstrating complete eradication of colonic C. difficile by day three of treatment as well as the observed overgrowth of healthy gut microbiota Actinobacteria and Firmicute phyla species during and after therapy. According to Dr. Garey, “The good tolerability, promising efficacy outcomes, minimal systemic exposure, and differential microbiome effects relative to vancomycin all support the continued clinical development of ibezapolstat. #ibezapolstat #antibiotics #pennystocks #trendingstocks

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button